

K042141

July 21, 2004

page 1/2

**Section VI**  
**510(k) Summary**

SEP 28 2004

---

**Substantial Equivalence**

In accordance with the requirements of 21 CFR § 807, this summary is formatted with the Agency's final rule "... 510(k) Summaries and 510(k) Statements..." and can be used to provide equivalence summary to anyone requesting it from the Agency.

**Manufacturer**

Teleflex Medical  
600 Airport Road  
Fall River, MA 02720-4740

**Contact Person**

Steve Astorino  
Engineering Manager  
Phone: (508) 677-6589  
Fax: (508) 677-6663  
e-mail: sastorino@teleflexmedial.com

**Date Prepared**

July 21, 2004

**Device Information**

Trade Name: Polyglytone\*6211™ Synthetic Absorbable Suture.  
Common Name: Absorbable Surgical Suture.  
Classification Name: Absorbable Poly(glycolide/L-lactide) Surgical Suture

**Indications for Use**

Polyglytone\* 6211 sutures are indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic surgery but not for use in cardiovascular surgery, neurological surgery, or microsurgery.

**Device Description**

Polyglytone\* 6211 suture, U.S.P. size- 2-0, is available, undyed (natural). The suture is monofilament, may be provided in a variety of lengths, with or without needles, with or without pledgets, and may be supplied in a variety of cut lengths.

K042141

July 21, 2004

page 1/2

## **Section VI**

### **510(k) Summary**

---

#### **Substantial Equivalence**

The device is similar in intended use, materials, design, and performance characteristics to the currently cleared U.S. Surgical Caprosyn™ Monofilament Synthetic Absorbable Suture (K013671 & K032586).

The determination of substantial equivalence for this device was based on a detailed device description, performance testing and conformance with voluntary performance standards, e.g. ANSI/AAMI/ISO 10993-1 Biological Evaluation of Medical Devices, U.S.P.– Absorbable Surgical Sutures, and the FDA “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA”, June 3, 2003.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

SEP 28 2004

Mr. Steve Astorino  
Engineering Manager  
Teleflex Medical  
600 Airport Road  
Fall River, Massachusetts 02720

Re: K042141  
Trade/Device Name: Polyglytone 6211™ Synthetic Absorbable Suture  
Regulation Number: 21 CFR 878.4493  
Regulation Name: Absorbable poly(glycolide/L lactide) surgical suture.  
Regulatory Class: II  
Product Code: GAM  
Dated: July 21, 2004  
Received: August 9, 2004

Dear Mr. Astorino:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Steve Astorino

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

*Miriam C. Provost*  
for  
Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K042141

Device Name: Polyglytone\*6211™ Synthetic Absorbable Suture

### Indications for Use:

---

Polyglytone\*6211™ Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic surgery but not for use in cardiovascular surgery, neurological surgery, or microsurgery.

Prescription Use  X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use   
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Miriam C. Provost*

**(Division Sign-Off)**

**Division of General, Restorative,  
and Neurological Devices**

Page 1 of 1  
(Posted November 13, 2003)

**510(k) Number** K042141